会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Pyrogallol synthesis of anti-atherogenic furochromones
    • 邻苯三酚合成抗动脉粥样硬化的呋喃色酮
    • US4459420A
    • 1984-07-10
    • US378686
    • 1982-05-17
    • Ronald B. Gammill
    • Ronald B. Gammill
    • A61K31/34A61K31/343A61K31/35A61P9/10C07D307/86C07D493/04C07D307/79
    • C07D493/04C07D307/86
    • The present invention provides a total synthesis of known intermediates useful in the synthesis of khellin and antiatherosclerotic analogs thereof from pyrogallol. Pyrogallol is converted to 3,6,7-benzofurantriol triacetate using zinc chloride and chloracetanitrile, then catalytically reduced and deactoxylated at the 3 position to yield the corresponding 2,3-dihydrofuran. This substance is subjected to a Fries rearrangement to the corresponding diol, the phenolic hydroxyl group of which is then selectively alkylated. This yields 6-hydroxy-7-alkoxy-5-benzofuranyl methyl ketone, a known intermediate for the production of 4-desmethoxy khellin and analogs thereof. This compound is then selectively alkoxylated at the 4 position using lead tetraacetate or thallium (III) nitrate in an alkanol solvent to yield known chemical intermediates in the preparation of khellin and analogs thereof.
    • 本发明提供了可用于合成来自邻苯三酚的凯辛及其抗动脉粥样硬化类似物的已知中间体的全合成。 使用氯化锌和氯乙腈将邻苯三酚转化为3,6,7-苯并呋喃三醇酯,然后在3位催化还原和脱氧化,得到相应的2,3-二氢呋喃。 将该物质进行Fries重排,然后将其酚羟基选择性烷基化成相应的二醇。 这得到6-羟基-7-烷氧基-5-苯并呋喃基甲基酮,其是生产4-脱甲氧基壳聚糖的公知中间体及其类似物。 然后使用四乙酸铅或硝酸铊在链烷醇溶剂中将该化合物在4位选择性烷氧基化,得到其制备凯辛及其类似物的已知化学中间体。
    • 8. 发明授权
    • Oxazolidinone antimicrobials containing substituted diazine moieties
    • 含有取代的二嗪部分的恶唑烷酮抗微生物剂
    • US5700799A
    • 1997-12-23
    • US610031
    • 1996-03-04
    • Douglas K. HutchinsonMichael R. BarbachynSteven J. BricknerRonald B. GammillMahesh V. Patel
    • Douglas K. HutchinsonMichael R. BarbachynSteven J. BricknerRonald B. GammillMahesh V. Patel
    • A61K31/395A61K31/42A61K31/421A61K31/422A61K31/495A61K31/496A61K31/551A61P31/00A61P31/04C07D263/20C07D263/24C07D413/10C07D413/12C07D413/14C07D245/02
    • C07D263/20C07D413/10C07D413/12
    • A compound of structural Formula I: ##STR1## or pharmaceutically acceptable salts thereof wherein: each n is independently 1 to 3; Y is choosen from a-n as defined herein; wherein each occurrence of said C.sub.1-6 alkyl may be substituted with one or more F, Cl, Br, I, OR.sup.1, CO.sub.2 R.sup.1, CN, SR.sup.1, or R.sup.1 (where R.sup.1 is a hydrogen or C.sub.1-4 alkyl); X and Z are independently C.sub.1-6 alkyl, C.sub.3-12 cycloalkyl or hydrogen, or X and Z form a C.sub.0-3 bridging group, preferably X and Z are hydrogen; U, V and W are independently C.sub.1-6 alkyl, F, Cl, Br, hydrogen or a C.sub.1-6 alkyl substituted with one or more of F, Cl, Br or I, preferably U and V are F and W is hydrogen; R is hydrogen, C.sub.1-12 alkyl, C.sub.3-12 cycloalkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkyl substituted with one or more F, Cl, Br, I or OH; and q is 0 to 4 inclusive. Oxazolidinone derivatives possessing a substituted diazine moiety bonded to the N-aryl ring are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including multiply-resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium avium.
    • 结构式I的化合物或其药学上可接受的盐,其中:每个n独立地为1至3; 从本文定义的a-n中选择Y; 其中所述C 1-6烷基的每次出现可以被一个或多个F,Cl,Br,I,OR1,CO 2 R 1,CN,SR 1或R 1(其中R 1是氢或C 1-4烷基)取代; X和Z独立地是C 1-6烷基,C 3-12环烷基或氢,或X和Z形成C0-3桥连基,优选X和Z是氢; U,V和W独立地是C 1-6烷基,F,Cl,Br,氢或被F,Cl,Br或I中的一个或多个取代的C 1-6烷基,优选U和V是F,W是氢; R是氢,C 1-12烷基,C 3-12环烷基,C 1-6烷氧基,被一个或多个F,Cl,Br,I或OH取代的C 1-6烷基; q为0〜4。 具有与N-芳基环结合的取代的二嗪部分的恶唑烷酮衍生物是有效的抗微生物剂,其对许多人类和兽医病原体有效,包括多重耐药性葡萄球菌和链球菌,以及厌氧生物体如杀菌剂和梭菌属物种,以及 耐酸生物如结核分枝杆菌和鸟分枝杆菌。